Hidradenitis Suppurativa Clinic, Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Instituto de Investigación Biosanitaria IBS, Granada, Spain.
J Dermatolog Treat. 2022 Feb;33(1):348-353. doi: 10.1080/09546634.2020.1755008. Epub 2020 Apr 21.
Hidradenitis suppurativa (HS) is a chronic debilitating autoinflammatory skin disease. Adalimumab is the only biologic agent available to treat HS, but lack of response is observed in some patients. Ustekinumab may be useful to treat patients with HS who do not respond to adalimumab.
The objectives of this study were: (1) to retrospectively evaluate the therapeutic outcomes of ustekinumab in a multicenter series of patients with HS and (2) to assess all published scientific evidence on its utilization in patients with HS.
We evaluated the therapeutic outcomes of 10 patients with HS treated with ustekinumab and conducted a systematic review of published epidemiological studies on ustekinumab-treated patients with HS.
In the case series, an improvement in the Physician Global Assessment score was observed in 70% (7/10) patients and an improvement in the Numerical Pain Rating Scale in 80% (8/10). In the systematic review, clinical improvement in disease severity was reported in 76% (34/45) patients and symptomatic improvement in 84% (38/45). No severe ustekinumab-related adverse event was recorded.
These findings suggest that ustekinumab may be an effective and safe option for patients with HS who fail to respond to first-line therapies.
化脓性汗腺炎（HS）是一种慢性衰弱性自身炎症性皮肤病。阿达木单抗是唯一可用于治疗 HS 的生物制剂，但一些患者对其反应不佳。乌司奴单抗可能对那些对阿达木单抗无反应的 HS 患者有用。
本研究的目的是：（1）回顾性评估乌司奴单抗治疗 HS 患者的多中心系列治疗结果，（2）评估所有已发表的关于乌司奴单抗治疗 HS 患者的科学证据。
我们评估了 10 例接受乌司奴单抗治疗的 HS 患者的治疗结果，并对乌司奴单抗治疗 HS 患者的已发表流行病学研究进行了系统评价。
在病例系列中，70%（7/10）的患者的医生总体评估评分得到改善，80%（8/10）的患者的数字疼痛评分量表得到改善。在系统评价中，76%（34/45）的患者报告疾病严重程度得到临床改善，84%（38/45）的患者报告症状得到改善。未记录到严重的乌司奴单抗相关不良事件。
这些发现表明，乌司奴单抗可能是对一线治疗无反应的 HS 患者的有效且安全的选择。
